Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00176527 · ClinicalTrials.gov registry record · Phase 2
Isotretinoin, Interferon Alfa-2b, Docetaxel, and Estramustine in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
A Phase 2 study, sponsored by University of Medicine and Dentistry of New Jersey.
- Terminated
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00176527: Clinical Trial Phase 2 study, sponsored by University of Medicine and Dentistry of New Jersey.
NCT00176527 is a Phase 2 study that was terminated before completion, run by University of Medicine and Dentistry of New Jersey. The registered enrollment target is 40 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (70% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00176527, a Phase 2 study, was terminated before completion, sponsored by University of Medicine and Dentistry of New Jersey.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
RATIONALE: Isotretinoin may help prostate cancer cells become more like normal cells, and to grow and spread more slowly. Interferon alfa-2b may interfere with the growth of tumor cells. Drugs used in chemotherapy, such as docetaxel and estramustine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving isotretinoin and interferon alfa-2b together with docetaxel and estramustine may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving isotretinoin and interferon alfa-2b together with docetaxel and estramustine works in treating patients with metastatic prostate cancer that did not respond to hormone therapy.
Interventions
- DRUG docetaxel
- BIOLOGICAL recombinant interferon alfa-2b
- DRUG estramustine phosphate sodium
- DRUG isotretinoin
- GENETIC polyacrylamide gel electrophoresis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2002-11 |
| Est. Completion | 2007-08 |
| Phase | Phase 2 |
Why NCT00176527 stopped before completion
NCT00176527 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (70% lower).
The record links to 0 conditions, and to 5 interventions - of which docetaxel is the first listed.
NCT00176527 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00176527 about?
NCT00176527 is a clinical study titled "Isotretinoin, Interferon Alfa-2b, Docetaxel, and Estramustine in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy". RATIONALE: Isotretinoin may help prostate cancer cells become more like normal cells, and to grow and spread more slowly. Interferon alfa-2b may interfere with the growth of tumor cells. Drugs used in chemotherapy, such as docetaxel and estramustine, work in different ways to stop the growth of tumo...
What is the current status of trial NCT00176527?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2002-11. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00176527?
The interventions under investigation include: docetaxel (DRUG), recombinant interferon alfa-2b (BIOLOGICAL), estramustine phosphate sodium (DRUG), isotretinoin (DRUG), polyacrylamide gel electrophoresis (GENETIC).
Who is sponsoring clinical trial NCT00176527?
This trial is sponsored by University of Medicine and Dentistry of New Jersey, which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00176527's enrollment target sits among peer trials
40 1362nd of 2000 higher than 542 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia